Kathleen Moore, MD

Dr Moore on Key 2024 Updates in FRα+ Ovarian Cancer Management

November 27th 2024

Dr Moore on Ongoing ADC Development in Ovarian Cancer

November 27th 2024

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates under investigation in ovarian cancer.

Dr Moore on the Evolving Treatment Landscape for Platinum-Resistant Ovarian Cancer

November 4th 2024

Kathleen N. Moore, MD, MS, discusses the evolving landscape in managing platinum-resistant ovarian cancer.

Dr Moore on Continued Efforts to Utilize Immunotherapy in Ovarian Cancer

November 21st 2023

Kathleen N. Moore, MD, MS, discusses continued efforts to target the immune system in ovarian cancer through the use of immunotherapy, as well as alternative strategies being explored in this tumor type.

Dr Moore on the Design of a Phase 1/2 Study of Ubamatamab in Ovarian Cancer

September 6th 2023

Kathleen N. Moore, MD, MS, discusses the design of the ongoing, first-in-human, phase 1/2 study of the MUC16- and CD3-targeted bispecific antibody ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr Moore on Investigating Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

July 29th 2023

Kathleen N. Moore, MD, MS, discusses the investigation of ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Unmet Needs and Clinical Pearls for Metastatic Endometrial Cancer

November 1st 2022

Before closing out their conversation on endometrial cancer, Kathleen Moore and David O’Malley summarize unmet needs in the field and share a few clinical pearls on managing patients with the disease.

Dr. Moore on the Investigation of Nab-sirolimus in TSC1/2-Mutated Gynecologic Cancers and Other Solid Tumors

October 27th 2022

Kathleen N. Moore, MD, MS, discusses the investigation of nab-sirolimus in TSC1/2-mutated gynecologic cancers.

Emerging Biomarkers and Drug Targets in mEC

October 25th 2022

Shared insight into novel biomarkers and potential drug targets being explored for treatment of metastatic endometrial cancer.

Looking Towards the Future: Moving Targeted Therapies for mEC Into the First-Line Setting

October 25th 2022

Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.

Considerations for Second-Line and Higher Treatment of Recurrent mEC

October 18th 2022

Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.

First-Line Therapy for dMMR mEC: Patient Conversations and Treatment Goals

October 18th 2022

Comprehensive discussion on patient counseling, and treatment goals, and expectations for those beginning first-line chemotherapy for dMMR metastatic endometrial cancer.

Expert Commentary on the Patient’s Treatment Plan

October 11th 2022

Expert oncologists discuss the patient’s first-line treatment plan and comment on how they would have approached her care.

A Review of mEC Incidence and Prognosis and Introduction of the Clinical Case

October 11th 2022

Drs Kathleen Moore and David O’Malley share their perspectives on the incidence and prognosis of mEC, including mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) disease, and then review a scenario of a patient with dMMR mEC who was treated with first-line carboplatin/paclitaxel.

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer

September 2nd 2020

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Dr. Moore on the Prevalence of Ovarian Cancer

July 29th 2020

Kathleen Moore, MD, discusses the current prevalence of ovarian cancer.

Dr. Moore on Unmet Clinical Needs in Platinum-Resistant Ovarian Cancer

July 17th 2020

Kathleen Moore, MD, discusses the unmet clinical needs in platinum-resistant ovarian cancer.

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian Cancer

April 3rd 2020

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2020

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

March 4th 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.